發送短信 : A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

  ______    _____    __   _     ______    _  _   
 /_   _//  |  ___|| | || | ||  /_   _//  | \| || 
   | ||    | ||__   | '--' ||   -| ||-   |  ' || 
  _| ||    | ||__   | .--. ||   _| ||_   | .  || 
 /__//     |_____|| |_|| |_||  /_____//  |_|\_|| 
 `--`      `-----`  `-`  `-`   `-----`   `-` -`